Why does AOD-9604 not elevate IGF-1 like full HGH?

AOD-9604 represents only the C-terminal fragment (residues 176 to 191) of HGH and lacks the receptor-binding domain responsible for full GH receptor activation at the liver and other tissues that drives IGF-1 production. Its adipose effects are mediated through a distinct mechanism involving beta-3 adrenergic receptors rather than through the classical GH receptor signaling pathway, which is why it produces lipolysis without the IGF-1 elevation, anabolic effects, or diabetogenic properties of full HGH.

What clinical research has been conducted on AOD-9604?

AOD-9604 progressed through Phase 1 and Phase 2a clinical trials for obesity treatment. The Phase 2a studies examined multiple doses over 12-week periods in obese subjects, documenting modest but measurable fat reduction at specific doses without significant adverse effects. The compound did not advance to Phase 3 trials, but the Phase 2a human data provides a safety and preliminary efficacy context that distinguishes it from purely preclinical compounds. The FDA also granted AOD-9604 GRAS (Generally Recognized As Safe) status for use as a food additive.

How does AOD-9604 compare to GLP-1 agonists in fat metabolism research?

AOD-9604 acts directly on adipose tissue through beta-3 adrenergic receptor interaction to stimulate lipolysis, an adipocyte-specific mechanism. GLP-1 agonists act primarily through hypothalamic appetite suppression and pancreatic insulin secretion enhancement, reducing adiposity mainly through caloric intake reduction and improved insulin sensitivity. AOD-9604 is a more targeted lipolysis tool; GLP-1 agonists act on multiple metabolic axes simultaneously. Research designs comparing these approaches examine different mechanistic contributions to fat loss outcomes.

What is the GRAS status of AOD-9604?

The FDA awarded AOD-9604 GRAS (Generally Recognized As Safe) designation for use as a food additive based on its human clinical trial safety data. This designation reflects the compound safety profile documented in the Phase 2a obesity trials rather than any approval for therapeutic use. It is one of the few research peptides with an FDA GRAS designation, which provides a safety context for researchers evaluating it in metabolic study designs.

Compound Reference

AOD-9604

An HGH C-terminal fragment studied for adipose-specific lipolysis stimulation without IGF-1 elevation or anabolic growth hormone effects.

HGH fragment (residues 176-191)C₇₈H₁₂₃N₂₃O₂₃S₂Approx. 30 to 60 minutes (preclinical)

Adipose LipolysisMetabolic ResearchFat-Specific GH ActivityBody CompositionObesity Models

Overview

AOD-9604 is a synthetic peptide corresponding to residues 176 to 191 of the C-terminal region of human growth hormone (HGH), with an additional disulfide bridge. It was developed by researchers at Monash University and studied through Phase 2a human clinical trials for obesity treatment. AOD-9604 stimulates lipolysis in adipose tissue through interactions with beta-3 adrenergic receptors, producing fat-specific metabolic effects without engaging the full HGH receptor in a manner that elevates IGF-1 or produces the anabolic effects of full-length growth hormone. This selective fat-metabolism profile without systemic GH receptor activation makes it a distinct tool in metabolic research.

Quick Reference

Structure: HGH residues 176-191 with disulfide bridge
Development origin: Monash University; Advanced Medical Institute
Clinical history: Completed Phase 2a obesity trials
GRAS status: Designated GRAS (Generally Recognized As Safe) by FDA for food use
Purity standard: >=98% by HPLC

Mechanism

How It Works

AOD-9604 stimulates lipolysis in adipose tissue through beta-3 adrenergic receptor interaction, activating the cAMP/PKA pathway in adipocytes to promote triglyceride breakdown and fatty acid release. Unlike full HGH, it does not bind the GH receptor in a manner that elevates IGF-1, produces hyperglycemia, or drives anabolic protein synthesis, making it a research tool for studying the fat metabolism component of GH biology in isolation.

Research Highlights

Key findings from the published preclinical literature.

Phase 2a Human Trial for Obesity

AOD-9604 completed Phase 2a clinical trials for obesity treatment in the early 2000s, with short-term studies documenting modest fat reduction effects at specific doses, establishing a human safety and preliminary efficacy profile for this HGH fragment.

Adipose-Specific Lipolysis Without IGF-1 Elevation

Research has documented that AOD-9604 stimulates lipolysis in adipose tissue without significantly elevating IGF-1 or causing the glucose-elevating effects associated with full HGH, distinguishing it as a fat-metabolism-focused GH fragment research tool.

Beta-3 Adrenergic Receptor Interaction

Studies examining the mechanism of AOD-9604 adipose activity have documented beta-3 adrenergic receptor involvement, providing a receptor-level explanation for its adipocyte-specific effects on cAMP-driven lipolysis.

Comparison with Full HGH in Metabolic Models

Research comparing AOD-9604 with full-length HGH in fat metabolism assays has documented that AOD-9604 produces adipose lipolytic effects comparable to or exceeding those of full HGH while avoiding the IGF-1 elevation, weight gain in certain tissues, and glucose effects associated with full HGH administration.

Research Connections

Related research areas, stacks, and comparisons involving this compound.

Frequently Asked Questions

Source This Compound

AOD-9604 is available from Spartan Peptides at a minimum 98% HPLC-verified purity with batch-specific certificate of analysis. Domestic US supply, same-day dispatch before 2 PM EST. For in-vitro research use only.

View AOD-9604 Product Sourcing Guide

All compounds are strictly for in-vitro research use only and not intended for human consumption.

GLP-3(Reta) | Triple-Agonist Metabolic Research

NAD+ 750mg | Cellular Energy & DNA Repair Research

MOTS-c | Mitochondrial Metabolism Research Peptide

BPC-157 5mg | Tissue Repair & Gut Health Research